© 2021 MJH Life Sciences and Urology Times. All rights reserved.
© 2021 MJH Life Sciences™ and Urology Times. All rights reserved.
May 14, 2021
The antibody-drug conjugate received a priority review for patients with locally advanced or metastatic urothelial carcinoma with disease progression.
May 13, 2021
The FDA is scheduled to make a decision on the expanded approval for the antibody-drug conjugate on or before August 17, 2021.
May 07, 2021
The data from the pivotal phase 2 TROPHY-U-01 trial supported the FDA approval of sacituzumab govitecan for the treatment of patients with urothelial carcinoma.
May 05, 2021
“Our findings highlight an urgent need for more accurate, patient-friendly social media content,” says Dr. Stacy Loeb.
May 04, 2021
Final FDA decision on approvals is still pending.
April 30, 2021
The agency made the designation on the basis of recently reported data from the phase 3 CheckMate 274 trial that found a statistically significant improvement in disease-free survival in patients treated with the PD-1 inhibitor.
"After a long period of stagnation and inertia, the bladder cancer space is alive and full of innovation and activation," writes Michael S. Cookson, MD, MMHC.
April 23, 2021
Myriad therapies in the pipeline will change treatment landscape.
April 20, 2021
Padeliporfin ImPACT previously received FDA Fast Track and Orphan Drug designations for the treatment of patients with upper tract urothelial cancer.
April 19, 2021
The applications are supported by data from the EV-301 and EV-201 trials.